Catecholamine Diagnosis of Alzheimer's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease lack sensitivity and specificity, particularly in early detection, and there is a need for improved tools to differentiate Alzheimer's from other forms of dementia, as existing biomarkers and methods are not sufficient for reliable early diagnosis.
Innovation Solution
Measuring and combining the levels of dopamine, adrenaline, and noradrenaline in biological fluids using capillary electrophoresis, followed by a virtual value calculation, to diagnose Alzheimer's disease with enhanced sensitivity and specificity, potentially differentiating it from other neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing biomarkers (total Tau, phosphorylated Tau, Aβ1-42) and brain imaging methods are used for diagnosis, then diagnostic information can be obtained, but sensitivity and specificity remain insufficient for early and differential diagnosis
Solution Approach 1:
The patent combines multiple catecholamine measurements (dopamine, adrenaline, noradrenaline) into a composite diagnostic approach. By measuring and integrating the levels of these three catecholamines together rather than relying on single biomarkers, the method achieves enhanced diagnostic sensitivity and specificity for early Alzheimer's disease detection, directly resolving the contradiction between measurement precision and reliability
Solution Approach 2:
The patent introduces a novel diagnostic parameter - the combination ratio or composite value of multiple catecholamines (dopamine, adrenaline, noradrenaline). This new parameter configuration provides superior diagnostic discrimination compared to traditional single biomarkers, thereby improving both sensitivity and reliability simultaneously
2Measurement precision
If multiple biomarkers are measured to improve diagnostic accuracy, then sensitivity and specificity increase, but diagnostic complexity and cost increase
Solution Approach 1:
The patent employs a multi-functional diagnostic approach where a single catecholamine measurement system simultaneously evaluates three different catecholamines (dopamine, adrenaline, noradrenaline). This universal measurement platform achieves high diagnostic accuracy without requiring separate complex analytical systems for each biomarker, thus improving precision while controlling complexity
Solution Approach 2:
The patent transforms the diagnostic approach by using a standardized measurement technique to assess multiple related parameters (catecholamine levels) that can be processed through a unified algorithm. This parameter transformation allows complex multi-biomarker information to be integrated into a manageable diagnostic framework, maintaining methodological simplicity while achieving high precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high sensitivity and specificity in diagnosing Alzheimer's disease, improving upon existing methods by providing a cost-effective and reliable means for early detection and differentiation from other dementias, with the potential for therapeutic follow-up monitoring.
Implementation Method 1
measuring and combining the levels of at least two catecholamines performed directly on samples from a biological fluid of a patient to be diagnosed
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, wherein the level of each of at least two catecholamines is measured in a sample of biological fluid from said subject.